*2.6.4 Amyloid removal [immunotherapy]*

Although it is not proven (exactly) how immunotherapy might attenuate Aβ plaques in the brain, some mechanisms have postulated. Therapeutic goal is to induce a humoral immune response to fibrillary-Aβ42 or passive administration of anti-Aβ antibodies. First studies of active vaccination were halted because of the induction of serious side effects. There are ongoing phase I–III studies with active and passive immunization (CAD106, bapineuzumab, solanezumab, intravenous immunoglobulin) [18].
